Truist raised the firm’s price target on Harmony Biosciences (HRMY) to $29 from $25 and keeps a Hold rating on the shares after meeting with the company’s management team. Wakix has a reasonable path to achieving FY26 guidance of over $1B, supported in part by the recent 20% expansion of the sales force, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Ami Fadia Reiterates Buy on Harmony Biosciences, Raises Price Target to $45 on Solid Wakix Demand and Reaffirmed 2026 Revenue Guidance
- Harmony Biosciences reports Q1 EPS 55c, consensus 93c
- Harmony Biosciences backs FY26 revenue view $1B-$1.04B, consensus $1.02B
- H.C. Wainwright views weakness in Harmony shares as ‘excessive IP overhang’
- Harmony Biosciences price target raised to $72 from $62 at Oppenheimer